Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Adelia Acquisition Making Impact, Reaching Milestones
Cybin subsidiary achieved certain milestones as outlined in acquisition agreementAdelia brought numerous advantages to companyAcquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain…